Broad RNAi Intellectual Property definition

Broad RNAi Intellectual Property means all Know-How and Patent Rights now or in the future owned or licensed by Alnylam or its Affiliates that relate to RNAi technology, products or processes, including (a) the general structure, architecture, or design of nucleic acid based molecules which engage RNAi mechanisms in a cell; (b) chemical modifications of nucleic acids (including any modification to the base, sugar or internucleoside linkage, nucleotide mimetics, and any end modifications) which do not abolish the RNAi activity of the nucleic acid molecules in (a); (c) manufacturing techniques for the nucleic acid based molecules or chemical modifications of (a) and (b); and (d) all uses or applications of nucleic acid based molecules or chemical modifications in (a) or (b); but excluding Patents which relates solely to (i) a specific Target or small group of Targets; or (ii) delivery technologies which may be broadly employed for delivery of nucleic acid based molecules.
View Source
Broad RNAi Intellectual Property means Broad RNAi Know-How and Broad RNAi Patent Rights.
View Source

Examples of Broad RNAi Intellectual Property in a sentence

  • Once Novartis acquires the Adoption License, Alnylam will periodically deliver to Novartis all Broad RNAi Intellectual Property.

  • Novartis grants Alnylam a worldwide, non-exclusive, sublicenseable (solely to Controlled Contractors) license under such jointly-created IP that is Broad RNAi Intellectual Property, to engage in any and all research activities directed to human, veterinary or agricultural applications.

  • In the course of acquiring or licensing additional Broad RNAi Intellectual Property or any other Alnylam Intellectual Property covering a Collaboration Product, Alnylam must use its best efforts to ensure that such rights include the right to sublicense to Novartis such Broad RNAi Intellectual Property or other Alnylam Intellectual Property.

  • Novartis hereby grants to Alnylam a worldwide, non-exclusive, royalty-free right and license (sublicenseable solely to Controlled Contractors) under the Novartis Sole Inventions that, absent this Section 6.1(b), would have been Joint Intellectual Property that is Broad RNAi Intellectual Property, to engage in any and all research activities directed to the Field.

  • If Novartis so notifies Alnylam that such Target is the subject of a Dedicated Novartis Program, Alnylam shall not grant to such Pre-Existing Alliance Party the requested rights under the Broad RNAi Intellectual Property with respect to such Target.

  • Following the Adoption Date, on a periodic basis as agreed by the Parties, and promptly following Novartis's reasonable request from time to time, Alnylam shall deliver to Novartis, for no additional consideration, all Broad RNAi Intellectual Property that is necessary or useful to the exercise of Novartis's rights under the Adoption License.

  • If Novartis so notifies Alnylam that such Target is not the subject of a Dedicated Novartis Program, then Alnylam may grant to such Pre-Existing Alliance Party the relevant rights under Broad RNAi Intellectual Property with respect to such Target, and Novartis's rights under Sections 3.1(a) or (c) shall be subject to such Pre-Existing Alliance Party's rights with respect to such Target.

  • In connection with Novartis's bona fide consideration of acquiring the Adoption License, Alnylam shall afford Novartis and its attorneys and authorized representatives reasonable access to all relevant Patent Rights files, contracts, correspondence, records and Patent personnel of Alnylam and its Affiliates in order to permit Novartis to conduct due diligence with respect to the Broad RNAi Intellectual Property.

  • In the course of acquiring or licensing additional Broad RNAi Intellectual Property or any other Alnylam Intellectual Property Covering a Collaboration Product, Alnylam shall use its best efforts to ensure that such rights include the right to sublicense to Novartis such Broad RNAi Intellectual Property or any other Alnylam Intellectual Property Covering a Collaboration Product.

  • Alnylam may not grant any exclusive rights or licenses under any Broad RNAi Intellectual Property except with respect to an opportunity Novartis does not acquire under the ROFO or in accordance with agreements existing before the effective date of the Novartis Agreement.